SG152285A1 - Solid pharmaceutical formulation - Google Patents

Solid pharmaceutical formulation

Info

Publication number
SG152285A1
SG152285A1 SG200902964-6A SG2009029646A SG152285A1 SG 152285 A1 SG152285 A1 SG 152285A1 SG 2009029646 A SG2009029646 A SG 2009029646A SG 152285 A1 SG152285 A1 SG 152285A1
Authority
SG
Singapore
Prior art keywords
pharmaceutical formulation
solid pharmaceutical
provides
formulation
gelatinized starch
Prior art date
Application number
SG200902964-6A
Other languages
English (en)
Inventor
Tadashi Mukai
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35428258&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG152285(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of SG152285A1 publication Critical patent/SG152285A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
SG200902964-6A 2004-05-20 2005-05-19 Solid pharmaceutical formulation SG152285A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004150557 2004-05-20

Publications (1)

Publication Number Publication Date
SG152285A1 true SG152285A1 (en) 2009-05-29

Family

ID=35428258

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200902964-6A SG152285A1 (en) 2004-05-20 2005-05-19 Solid pharmaceutical formulation

Country Status (15)

Country Link
US (1) US8821936B2 (ru)
EP (1) EP1755682A4 (ru)
KR (2) KR101302810B1 (ru)
CN (1) CN1984682B (ru)
AR (1) AR048970A1 (ru)
AU (1) AU2005244707B2 (ru)
BR (1) BRPI0511298A (ru)
CA (1) CA2567400C (ru)
HK (1) HK1105358A1 (ru)
MX (1) MXPA06013407A (ru)
MY (1) MY153696A (ru)
RU (1) RU2390332C2 (ru)
SG (1) SG152285A1 (ru)
TW (1) TWI338583B (ru)
WO (1) WO2005113009A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008032767A1 (fr) * 2006-09-14 2008-03-20 Astellas Pharma Inc. Comprimé se désintegrant oralement et procédé de fabrication de celui-ci
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
AR071706A1 (es) * 2008-05-15 2010-07-07 Otsuka Pharma Co Ltd Una formulacion farmaceutica de cilostazol solida de liberacion sostenida y metodo de preparacion.
EP3409294A1 (en) 2017-06-01 2018-12-05 Przedsiebiorstwo Farmaceutyczne Lek-Am Sp Z O. O. Tablets containing cilostazol of specific particle size distribution
RU2686066C1 (ru) * 2018-05-11 2019-04-24 Общество С Ограниченной Ответственностью "Валента-Интеллект" Лекарственная форма цилостазола замедленного высвобождения

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB825892A (en) * 1957-05-24 1959-12-23 Ici Ltd Tabletting process
US4266348A (en) * 1978-12-15 1981-05-12 Cpc International Inc. Fluidized bed process
GB8624213D0 (en) 1986-10-09 1986-11-12 Sandoz Canada Inc Sustained release pharmaceutical compositions
US4755397A (en) * 1986-12-24 1988-07-05 National Starch And Chemical Corporation Starch based particulate encapsulation process
FR2610827B1 (fr) 1987-02-18 1991-09-13 Pf Medicament Comprime de dihydroergotamine (d.h.e.) du type a matrice hydrophile et son procede de fabrication
FR2618073B1 (fr) * 1987-07-16 1990-09-07 Pf Medicament Comprimes de type a matrice hydrophile a base de salbutamol et leur procede de preparation
US5073380A (en) * 1987-07-27 1991-12-17 Mcneil-Ppc, Inc. Oral sustained release pharmaceutical formulation and process
FR2666506A1 (fr) * 1990-09-07 1992-03-13 Pf Medicament Comprime a liberation prolongee a base de 5-mononitrate d'isosorbide et son procede de preparation.
CN1168102A (zh) 1995-01-10 1997-12-17 大制药株式会社 树脂微粒及含该树脂微粒的药用材料和药剂
JP4022269B2 (ja) * 1995-05-26 2007-12-12 協和醗酵工業株式会社 医薬組成物
WO1997004752A1 (en) 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
DK0869772T3 (da) * 1995-12-27 2002-01-21 Janssen Pharmaceutica Nv Bioadhæsiv fast doseringsform
CN1222317C (zh) * 1996-07-12 2005-10-12 第一制药株式会社 可迅速崩解的压模物质及其生产方法
ES2565163T3 (es) 1996-10-28 2016-03-31 General Mills, Inc. Imbibición y encapsulación de partículas de liberación controlada y producto encapsulado
JPH10182701A (ja) * 1996-12-26 1998-07-07 Sanei Toka Kk 溶出性向上粉末及びその製造方法
US6129932A (en) * 1997-09-05 2000-10-10 Merck & Co., Inc. Compositions for inhibiting platelet aggregation
JPH11286456A (ja) 1998-03-31 1999-10-19 Lion Corp 複合粉体組成物及び錠剤
AU3780699A (en) 1998-05-01 1999-11-23 Rt Alamo Ventures, Inc. The treatment of sexual dysfunction in certain patient groups
EP1161941A4 (en) 1999-03-15 2002-08-28 Kaken Pharma Co Ltd FAST DELITING TABLETS AND MANUFACTURING METHOD
EG23951A (en) * 1999-03-25 2008-01-29 Otsuka Pharma Co Ltd Cilostazol preparation
JP4748839B2 (ja) 1999-03-25 2011-08-17 大塚製薬株式会社 シロスタゾール製剤
EA005291B1 (ru) 1999-03-31 2004-12-30 Янссен Фармацевтика Н.В. Применение предварительно желатинированного крахмала в композиции с контролируемым высвобождением
FR2798289B1 (fr) * 1999-09-15 2004-12-31 Cll Pharma Formes galeniques a delitement rapide en bouche et leur procede de preparation
US7138143B1 (en) * 1999-09-30 2006-11-21 Otsuka Pharmaceutical Company, Limited Coated preparation soluble in the lower digestive tract
IL151838A0 (en) * 2000-03-20 2003-04-10 Teva Pharma Processes for preparing 6-hydroxy-3,4-dihydroquinolinone, cilostazol and n- (4-methoxyphenyl)-3-chloropropionamide
US6515128B2 (en) * 2000-03-20 2003-02-04 Teva Pharmaceutical Industries Ltd. Processes for preparing cilostazol
JP4637338B2 (ja) * 2000-09-22 2011-02-23 大塚製薬株式会社 シロスタゾール有核錠
JP2002193792A (ja) * 2000-12-25 2002-07-10 Lion Corp フィルムコーティング錠剤及びエロージョン防止組成物
JP2003063965A (ja) 2001-06-13 2003-03-05 Otsuka Pharmaceut Factory Inc 注射用シロスタゾール水性製剤
US6509040B1 (en) * 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
US6596871B2 (en) * 2001-06-29 2003-07-22 Grayson Walker Stowell Polymorphic forms of 6-[4-(1-cyclohexyl-1h-tetraol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone
US6388080B1 (en) * 2001-06-29 2002-05-14 Grayson Walker Stowell Polymorphic forms of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone
US6531603B1 (en) * 2001-06-29 2003-03-11 Grayson Walker Stowell Polymorphic forms of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone
CN1210026C (zh) * 2002-10-09 2005-07-13 重庆太极医药研究院 褪黑素双层控释片及制备工艺
MXPA05004422A (es) 2002-10-25 2007-11-22 Collegium Pharmaceutical Inc Composiciones de milnacipran de liberacion pulsatil.
US20050255155A1 (en) * 2004-05-11 2005-11-17 Glenmark Pharmaceuticals Limited Modified release cilostazol compositions

Also Published As

Publication number Publication date
US20080033009A1 (en) 2008-02-07
CA2567400A1 (en) 2005-12-01
TW200538161A (en) 2005-12-01
KR20070034002A (ko) 2007-03-27
MXPA06013407A (es) 2007-01-23
CN1984682B (zh) 2012-06-06
WO2005113009A1 (en) 2005-12-01
EP1755682A4 (en) 2012-11-07
KR101302810B1 (ko) 2013-09-02
RU2006145311A (ru) 2008-07-10
MY153696A (en) 2015-03-13
AR048970A1 (es) 2006-06-14
TWI338583B (en) 2011-03-11
CA2567400C (en) 2012-09-25
US8821936B2 (en) 2014-09-02
AU2005244707B2 (en) 2011-08-11
KR20120030606A (ko) 2012-03-28
RU2390332C2 (ru) 2010-05-27
EP1755682A1 (en) 2007-02-28
AU2005244707A1 (en) 2005-12-01
HK1105358A1 (en) 2008-02-15
CN1984682A (zh) 2007-06-20
BRPI0511298A (pt) 2007-12-04

Similar Documents

Publication Publication Date Title
WO2007048219A3 (en) Sustained drug release composition
WO2008107149A3 (de) Darreichungsform mit erschwertem missbrauch
WO2004112711A3 (en) Oral extended-release composition
WO2007008752A3 (en) Sustained release pharmaceutical compositions for highly water soluble drugs
WO2004012700A3 (en) Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
WO2002074247A8 (en) Pharmaceutical formulations for sustained release
MX2007000008A (es) Formas farmaceuticas orales, protegidas frente al abuso, que contienen (1r,2r)-3-(3-dimetilamino-1-etil-2-metil-propil) fenol.
WO2002070438A3 (en) Compositions for delivering bisphosphonates
WO2002019969A3 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
DK1256343T3 (da) Flibanserin til behandlingen af extrapyramidale bevægelseslidelser
CO5060477A1 (es) Forma de dosificacion de nefazodona
HRP20050342B1 (hr) Farmaceutska formulacija olanzapina
IL158668A0 (en) Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
WO2006053089A3 (en) Methods and formulations for making pharmaceutical compositions containing bupropion
SG152285A1 (en) Solid pharmaceutical formulation
WO2005065639A3 (en) Novel pharmaceutical compositions
IL179177A (en) A pharmaceutical product including acyclovir and delivery compound, dosage unit, use of acyclovir in the preparation of the pharmaceutical product, use of the pharmaceutical product in the preparation of a drug and a method for the preparation of the pharmaceutical product
WO2011083402A3 (en) Immediate release compositions of acid labile drugs
MY153109A (en) A solid pharmaceutical formulation
WO2008004100A3 (en) Therapeutic compounds
UA89656C2 (ru) Фармацевтическая композиция, которая диспергируется перорально, и способ ее приготовления
WO2007031326A3 (de) Retardformulierung von 3-(2-dimethylaminomethyl-cyclohexyl)-phenol
TNSN06072A1 (en) Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep
WO2004071398A3 (en) Pharmaceutical patch